Skip to main content
. 2017 Feb 21;10:1101–1110. doi: 10.2147/OTT.S112158

Figure 1.

Figure 1

Gefitinib-induced changes of the peripheral lymphocyte subsets: (A) CD4+ T cells, (B) CD8+ T cells, (C) NK cells, and (D) CD4+CD25+ T cells.

Note: The changes of lymphocyte in terms of percent of PBMCs were analyzed for all patients (n=54) at baseline and 4 weeks after gefitinib treatment.

Abbreviation: PBMC, peripheral blood mononuclear cell.